{"pmid":32472461,"title":"COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.","text":["COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.","Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF alpha) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment.","Clin Rheumatol","Ouedraogo, Dieu-Donne","Tiendrebeogo, Wendlassida Joelle Stephanie","Kabore, Fulgence","Ntsiba, Honore","32472461"],"abstract":["Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF alpha) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment."],"journal":"Clin Rheumatol","authors":["Ouedraogo, Dieu-Donne","Tiendrebeogo, Wendlassida Joelle Stephanie","Kabore, Fulgence","Ntsiba, Honore"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472461","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10067-020-05189-y","keywords":["covid-19","coronavirus","rheumatoid arthritis","treatment"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668255193344507904,"score":9.490897,"similar":[{"pmid":32317220,"pmcid":"PMC7164894","title":"The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","text":["The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.","J Autoimmun","Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto","32317220"],"abstract":["The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection."],"journal":"J Autoimmun","authors":["Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317220","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaut.2020.102468","keywords":["autoimmunity","biologics","covid-19","coronavirus","dmards","il-6","immunosuppressant. il-1","infection","rheumatic","sars-cov-2","tdmards"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493622943744,"score":289.6675},{"pmid":32253068,"pmcid":"PMC7127009","title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","text":["Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.","J Autoimmun","Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo","32253068"],"abstract":["The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19."],"journal":"J Autoimmun","authors":["Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253068","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jaut.2020.102442","keywords":["antimalarials","baricitinib","covid-19","rheumatic diseases","sars-cov2","tocilizumab"],"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab","baricitinib"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493115432961,"score":277.0287},{"pmid":32474885,"title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","text":["Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.","Clin Rheumatol","Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet","32474885"],"abstract":["COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists."],"journal":"Clin Rheumatol","authors":["Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474885","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s10067-020-05190-5","keywords":["covid-19","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","macrophage activation syndrome"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668341932687884289,"score":245.52885},{"pmid":32303821,"pmcid":"PMC7163348","title":"[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].","text":["[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].","The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.","Z Rheumatol","Schmeiser, T","Broll, M","Dormann, A","Frabel, C","Hermann, W","Hudowenz, O","Keil, F","Muller-Ladner, U","Ozden, F","Pfeiffer, U","Saech, J","Schwarting, A","Stapfer, G","Steinchen, N","Storck-Muller, K","Strunk, J","Thiele, A","Triantafyllias, K","Wassenberg, S","Wilden, E","Hasseli, R","32303821"],"abstract":["The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society."],"journal":"Z Rheumatol","authors":["Schmeiser, T","Broll, M","Dormann, A","Frabel, C","Hermann, W","Hudowenz, O","Keil, F","Muller-Ladner, U","Ozden, F","Pfeiffer, U","Saech, J","Schwarting, A","Stapfer, G","Steinchen, N","Storck-Muller, K","Strunk, J","Thiele, A","Triantafyllias, K","Wassenberg, S","Wilden, E","Hasseli, R"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303821","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00393-020-00800-8","keywords":["antirheumatic therapy","covid-19","patient questionnaire","rheumatic diesease"],"topics":["Treatment"],"weight":1,"_version_":1666138491131527168,"score":220.33246},{"pmid":32473418,"title":"Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.","text":["Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.","BACKGROUND: Rheumatologists must contend with COVID-19 pandemic in the management of their patients and many questions have been raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARD). The French Society of Rheumatology (SFR) selected the most critical ones to the daily practice of a rheumatologist and a group of 10 experts from SFR and Club Rheumatism and Inflammation (CRI) boards proposed responses based on the current knowledge of May 2020. BASIC PROCEDURE: Following the availability of the first 18 questions and statements, 1400 individuals consulted the frequently asked questions between the March 31, 2020 and April 12, 2020. As a result, 16 additional questions were forwarded to the SFR, and answered by the board. An additional round of review by email and video conference was organized, which included updates of the previous statements. The scientific relevance of 5 of the questions led to their inclusion in this document. Each response received a final assessment on a scale of 0-10 with 0 meaning no agreement whatsoever and 10 being in complete agreement. The mean values of these votes for each question are presented as the levels of agreement (LoA) at the end of each response. This document was last updated on April 17, 2020. MAIN FINDINGS: Based on current scientific literature already published, in most circumstances, there is no contraindication to the initiation or continuation of anti-inflammatory drugs as well as DMARDs. If signs suggestive of infection (coronavirus or other) occurs, treatments should be discontinued and resumed, if necessary, after 2 weeks without any symptoms. Only, some signals suggest that people taking an immunosuppressive dose of corticosteroid therapy are at greater risk of developing severe COVID-19. Intra-articular injections of glucocorticoids are allowed when there is no reasonable therapeutic alternative, and providing that precautions to protect the patient and the practitioner from viral contamination are adopted, included appropriate information to the patient. PRINCIPAL CONCLUSIONS: Currently available data on managing patients with rheumatic diseases during the COVID-19 pandemic are reassuring and support continuing or initiating symptomatic as well as specific treatments of these diseases, the main target of their management remaining their appropriate control, even during this pandemic.","Joint Bone Spine","Richez, Christophe","Flipo, Rene-Marc","Berenbaum, Francis","Cantagrel, Alain","Claudepierre, Pascal","Debiais, Francoise","Dieude, Philippe","Goupille, Philippe","Roux, Christian","Schaeverbeke, Thierry","Wendling, Daniel","Pham, Thao","Thomas, Thierry","32473418"],"abstract":["BACKGROUND: Rheumatologists must contend with COVID-19 pandemic in the management of their patients and many questions have been raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARD). The French Society of Rheumatology (SFR) selected the most critical ones to the daily practice of a rheumatologist and a group of 10 experts from SFR and Club Rheumatism and Inflammation (CRI) boards proposed responses based on the current knowledge of May 2020. BASIC PROCEDURE: Following the availability of the first 18 questions and statements, 1400 individuals consulted the frequently asked questions between the March 31, 2020 and April 12, 2020. As a result, 16 additional questions were forwarded to the SFR, and answered by the board. An additional round of review by email and video conference was organized, which included updates of the previous statements. The scientific relevance of 5 of the questions led to their inclusion in this document. Each response received a final assessment on a scale of 0-10 with 0 meaning no agreement whatsoever and 10 being in complete agreement. The mean values of these votes for each question are presented as the levels of agreement (LoA) at the end of each response. This document was last updated on April 17, 2020. MAIN FINDINGS: Based on current scientific literature already published, in most circumstances, there is no contraindication to the initiation or continuation of anti-inflammatory drugs as well as DMARDs. If signs suggestive of infection (coronavirus or other) occurs, treatments should be discontinued and resumed, if necessary, after 2 weeks without any symptoms. Only, some signals suggest that people taking an immunosuppressive dose of corticosteroid therapy are at greater risk of developing severe COVID-19. Intra-articular injections of glucocorticoids are allowed when there is no reasonable therapeutic alternative, and providing that precautions to protect the patient and the practitioner from viral contamination are adopted, included appropriate information to the patient. PRINCIPAL CONCLUSIONS: Currently available data on managing patients with rheumatic diseases during the COVID-19 pandemic are reassuring and support continuing or initiating symptomatic as well as specific treatments of these diseases, the main target of their management remaining their appropriate control, even during this pandemic."],"journal":"Joint Bone Spine","authors":["Richez, Christophe","Flipo, Rene-Marc","Berenbaum, Francis","Cantagrel, Alain","Claudepierre, Pascal","Debiais, Francoise","Dieude, Philippe","Goupille, Philippe","Roux, Christian","Schaeverbeke, Thierry","Wendling, Daniel","Pham, Thao","Thomas, Thierry"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473418","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jbspin.2020.05.006","keywords":["covid-19","health system","inflammatory rheumatic diseases","treatment"],"locations":["Intra"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668255193383305218,"score":219.10379}]}